

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



和 鉑 醫 藥 控 股 有 限 公 司

HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 02142)

**VOLUNTARY ANNOUNCEMENT
HARBOUR BIOMED AND DANA-FARBER CANCER INSTITUTE
COLLABORATE TO ADVANCE NOVEL BIOTHERAPIES
FOR CANCER TREATMENT**

This announcement is made by HBM Holdings Limited (the “**Company**” or “**Harbour BioMed**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board of directors of the Company is pleased to announce that the Company has entered into a multi-year, multifaceted research collaboration agreement with Dana-Farber Cancer Institute (“**Dana-Farber**”) to co-develop novel biotherapies in cancer treatment.

The Company scientists and Dana-Farber researchers will be working together to develop novel oncologic drugs, including bispecific antibodies and CAR-T cell products. In recent years, bispecific antibodies and CAR-T cell therapies are both considered as the next-generation solutions in the tumor immunology field. For their ability to engage two different targets, bispecific antibodies are expected to extend the possibilities of monoclonal antibody (mAb) therapeutics, and CAR-T cell therapy is an innovative immunotherapy that uses specially altered T-cells to redirect them to target cancer cells.

This strategic collaboration will leverage the Company’s transgenic Harbour Mice[®] platform with Dana-Farber’s expertise in CAR-T cell development and basic oncology research to generate novel biotherapies.

The Company’s antibody technology platform Harbour Mice[®], which is based on two proprietary transgenic mouse platforms, will be utilized to generate human therapeutic antibodies. The platforms have broad potential for generating both conventional as well as next-generation biologics, such as bi-and multi-specifics, CAR-T or VH domain-derived products that are fully human, affinity matured with excellent solubility and developability.

About Dana-Farber

Dana-Farber Cancer Institute is a teaching hospital of Harvard Medical School. Dana-Farber is committed to providing cancer patients with the best cancer care possible today, while advancing tomorrow's cures through intensive basic and clinical research. It is a leader in the development of national cancer treatment guidelines and improving the quality and effectiveness of cancer care. Its unique model of multidisciplinary, compassionate, and collaborative care puts patients and their families at the center of all that it does. The areas of expertise include breast cancer, skin cancer, gynecological cancers, lung cancer, stem cell transplants, and cancer clinical trials.

Cautionary Statement: We cannot guarantee that we will be able to successfully develop or ultimately market the products under this strategic collaboration. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 16 June, 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang and Dr. Mai-Jing Liao as executive Directors; Mr. Yu Min Qiu, Mr. Junfeng Wang and Ms. Weiwei Chen as non-executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Mr. Ka Chi Yau as independent non-executive Directors.